Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Voyager Therapeutics, Inc. (VYGR) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Voyager Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1640266.
Total stock buying since 2015: $93,793,045.
Total stock sales since 2015: $24,350,253.
Total stock option exercises since 2015: $758,488.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 96,515 | $393,336 | 0 | $0 |
| 2024 | 0 | $0 | 48,010 | $379,655 | 0 | $0 |
| 2023 | 4,395,588 | $39,032,821 | 1,707,262 | $14,485,023 | 10,000 | $28,500 |
| 2022 | 477,400 | $2,662,149 | 1,013,806 | $6,216,599 | 0 | $0 |
| 2021 | 0 | $0 | 30,040 | $220,186 | 0 | $0 |
| 2020 | 0 | $0 | 24,148 | $306,224 | 0 | $0 |
| 2019 | 4,179,728 | $50,002,086 | 0 | $0 | 0 | $0 |
| 2018 | 11,000 | $205,299 | 75,022 | $1,711,568 | 64,039 | $729,988 |
| 2017 | 0 | $0 | 43,920 | $637,662 | 0 | $0 |
| 2016 | 10,000 | $140,690 | 0 | $0 | 0 | $0 |
| 2015 | 125,000 | $1,750,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 19,000 | $70,870 | 0 | $0 |
| 2025-04 | 0 | $0 | 20,971 | $71,929 | 0 | $0 |
| 2025-02 | 0 | $0 | 52,266 | $228,716 | 0 | $0 |
| 2025-01 | 0 | $0 | 4,278 | $21,821 | 0 | $0 |
| 2024-10 | 0 | $0 | 5,999 | $34,914 | 0 | $0 |
| 2024-04 | 0 | $0 | 13,472 | $132,860 | 0 | $0 |
| 2024-02 | 0 | $0 | 24,730 | $184,610 | 0 | $0 |
| 2024-01 | 0 | $0 | 3,809 | $27,271 | 0 | $0 |
| 2023-10 | 0 | $0 | 13,567 | $94,833 | 0 | $0 |
| 2023-09 | 0 | $0 | 10,500 | $85,680 | 5,000 | $14,250 |
| 2023-07 | 0 | $0 | 5,500 | $59,400 | 0 | $0 |
| 2023-06 | 0 | $0 | 5,000 | $57,050 | 5,000 | $14,250 |
| 2023-04 | 0 | $0 | 8,696 | $68,088 | 0 | $0 |
| 2023-03 | 0 | $0 | 10,257 | $79,593 | 0 | $0 |
| 2023-02 | 4,395,588 | $39,032,821 | 136,342 | $1,257,112 | 0 | $0 |
| 2023-01 | 0 | $0 | 1,517,400 | $12,783,267 | 0 | $0 |
| 2022-08 | 0 | $0 | 962,243 | $5,883,285 | 0 | $0 |
| 2022-07 | 0 | $0 | 23,403 | $156,799 | 0 | $0 |
| 2022-06 | 477,400 | $2,662,149 | 0 | $0 | 0 | $0 |
| 2022-04 | 0 | $0 | 4,313 | $35,581 | 0 | $0 |
| 2022-03 | 0 | $0 | 12,017 | $101,963 | 0 | $0 |
| 2022-02 | 0 | $0 | 8,502 | $29,493 | 0 | $0 |
| 2022-01 | 0 | $0 | 3,328 | $9,478 | 0 | $0 |
| 2021-05 | 0 | $0 | 3,516 | $14,169 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | Ferguson Toby (Chief Medical Officer) | Sale | 19,000 | 3.73 | 70,870 |
| 2025-04-02 | Ferguson Toby (Chief Medical Officer) | Sale | 10,086 | 3.43 | 34,594 |
| 2025-04-02 | Sandrock Alfred (President and CEO) | Sale | 10,885 | 3.43 | 37,335 |
| 2025-02-20 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 3,305 | 4.26 | 14,079 |
| 2025-02-20 | Swartz Robin (COO & CBO) | Sale | 3,894 | 4.25 | 16,549 |
| 2025-02-20 | Sandrock Alfred (President and CEO) | Sale | 11,702 | 4.24 | 49,616 |
| 2025-02-11 | Fahey Sandell Jacquelyn (Chief Legal Officer) | Sale | 4,358 | 4.45 | 19,393 |
| 2025-02-11 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 5,413 | 4.45 | 24,087 |
| 2025-02-11 | Swartz Robin (COO & CBO) | Sale | 6,950 | 4.45 | 30,927 |
| 2025-02-11 | Sandrock Alfred (President & CEO) | Sale | 16,644 | 4.45 | 74,065 |
| 2025-01-14 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 1,191 | 5.13 | 6,109 |
| 2025-01-14 | Swartz Robin (COO & CBO) | Sale | 3,087 | 5.09 | 15,712 |
| 2024-10-02 | Fahey Sandell Jacquelyn (Chief Legal Officer) | Sale | 5,999 | 5.82 | 34,914 |
| 2024-04-02 | Swartz Robin (Chief Operating Officer) | Sale | 1,357 | 9.88 | 13,407 |
| 2024-04-02 | Sandrock Alfred (President and CEO) | Sale | 12,115 | 9.86 | 119,453 |
| 2024-02-21 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 3,365 | 7.47 | 25,136 |
| 2024-02-21 | Swartz Robin (Chief Operating Officer) | Sale | 3,966 | 7.45 | 29,546 |
| 2024-02-21 | Pfreundschuh Peter P. (Chief Financial Officer) | Sale | 3,764 | 7.46 | 28,079 |
| 2024-02-21 | Sandrock Alfred (President and CEO) | Sale | 13,033 | 7.46 | 97,226 |
| 2024-02-20 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 602 | 7.68 | 4,623 |
| 2024-01-17 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 1,266 | 7.18 | 9,089 |
| 2024-01-17 | Swartz Robin (Chief Operating Officer) | Sale | 2,543 | 7.15 | 18,182 |
| 2023-10-03 | Pfreundschuh Peter P. (Chief Financial Officer) | Sale | 13,567 | 6.99 | 94,833 |
| 2023-09-15 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 10,500 | 8.16 | 85,680 |
| 2023-09-15 | Carter Todd Alfred (Chief Scientific Officer) | Option Ex | 5,000 | 2.85 | 14,250 |
| 2023-07-06 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 5,500 | 10.80 | 59,400 |
| 2023-06-30 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 5,000 | 11.41 | 57,050 |
| 2023-06-30 | Carter Todd Alfred (Chief Scientific Officer) | Option Ex | 5,000 | 2.85 | 14,250 |
| 2023-04-03 | Swartz Robin (Chief Operating Officer) | Sale | 1,259 | 7.83 | 9,857 |
| 2023-04-03 | Sandrock Alfred (President and CEO) | Sale | 7,437 | 7.83 | 58,231 |
| 2023-03-20 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 2,193 | 7.76 | 17,017 |
| 2023-03-20 | Swartz Robin (Chief Operating Officer) | Sale | 3,654 | 7.76 | 28,355 |
| 2023-03-20 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 4,410 | 7.76 | 34,221 |
| 2023-02-23 | Neurocrine Biosciences Inc (10% Owner) | Buy | 4,395,588 | 8.88 | 39,032,821 |
| 2023-02-17 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 738 | 7.45 | 5,498 |
| 2023-02-17 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 3,297 | 7.45 | 24,562 |
| 2023-02-13 | Carter Todd Alfred (Chief Scientific Officer) | Sale | 797 | 7.67 | 6,112 |
| 2023-02-13 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 2,868 | 7.67 | 21,997 |
| 2023-02-01 | Tepper Robert I (10% Owner) | Sale | 128,642 | 9.32 | 1,198,943 |
| 2023-01-31 | Tepper Robert I (10% Owner) | Sale | 185,000 | 9.25 | 1,711,250 |
| 2023-01-30 | Tepper Robert I (10% Owner) | Sale | 75,000 | 9.03 | 677,250 |
| 2023-01-27 | Tepper Robert I (10% Owner) | Sale | 50,000 | 9.02 | 451,000 |
| 2023-01-25 | Tepper Robert I (10% Owner) | Sale | 50,000 | 9.22 | 461,000 |
| 2023-01-24 | Tepper Robert I (10% Owner) | Sale | 100,000 | 9.27 | 927,000 |
| 2023-01-23 | Tepper Robert I (10% Owner) | Sale | 55,000 | 9.06 | 498,300 |
| 2023-01-20 | Tepper Robert I (10% Owner) | Sale | 100,000 | 9.15 | 915,000 |
| 2023-01-11 | Ecor1 Capital, Llc | Sale | 110,000 | 8.50 | 934,670 |
| 2023-01-10 | Ecor1 Capital, Llc | Sale | 336,400 | 8.05 | 2,709,365 |
| 2023-01-09 | Ecor1 Capital, Llc | Sale | 456,000 | 7.67 | 3,498,432 |
| 2022-08-25 | Tepper Robert I (10% Owner) | Sale | 200,000 | 6.22 | 1,244,000 |
| 2022-08-24 | Tepper Robert I (10% Owner) | Sale | 149,972 | 6.09 | 913,329 |
| 2022-08-16 | Tepper Robert I (10% Owner) | Sale | 128,456 | 6.04 | 775,874 |
| 2022-08-15 | Tepper Robert I (10% Owner) | Sale | 135,808 | 6.04 | 820,280 |
| 2022-08-12 | Tepper Robert I (10% Owner) | Sale | 348,007 | 6.12 | 2,129,802 |
| 2022-07-14 | Higgins Michael J | Sale | 13,891 | 6.70 | 93,069 |
| 2022-07-14 | Pierce Glenn | Sale | 9,512 | 6.70 | 63,730 |
| 2022-06-23 | Ecor1 Capital, Llc | Buy | 376,000 | 5.66 | 2,126,656 |
| 2022-06-21 | Ecor1 Capital, Llc | Buy | 101,400 | 5.28 | 535,493 |
| 2022-04-04 | Swartz Robin (Chief Operating Officer) | Sale | 1,527 | 8.25 | 12,597 |
| 2022-04-04 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 2,786 | 8.25 | 22,984 |
| 2022-03-21 | Swartz Robin (Chief Operating Officer) | Sale | 4,413 | 8.48 | 37,444 |
| 2022-03-21 | Burek Julie (VP, Finance) | Sale | 2,649 | 8.48 | 22,476 |
| 2022-03-21 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 4,955 | 8.48 | 42,043 |
| 2022-02-17 | Burek Julie (VP, Finance) | Sale | 789 | 3.55 | 2,800 |
| 2022-02-17 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 4,100 | 3.55 | 14,555 |
| 2022-02-11 | Burek Julie (VP, Finance) | Sale | 361 | 3.36 | 1,212 |
| 2022-02-11 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 3,252 | 3.36 | 10,926 |
| 2022-01-12 | Burek Julie (VP, Finance) | Sale | 265 | 3.06 | 810 |
| 2022-01-03 | Burek Julie (VP, Finance) | Sale | 3,063 | 2.83 | 8,668 |
| 2021-05-21 | Khwaja Omar (See remarks) | Sale | 3,516 | 4.03 | 14,169 |
| 2021-04-05 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 3,292 | 4.95 | 16,295 |
| 2021-02-11 | Khwaja Omar (See remarks) | Sale | 3,475 | 7.55 | 26,236 |
| 2021-02-11 | Dorval Allison (Chief Financial Officer) | Sale | 3,186 | 7.55 | 24,054 |
| 2021-02-11 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 3,186 | 7.55 | 24,054 |
| 2021-01-12 | Turenne Andre (President & CEO) | Sale | 10,443 | 8.62 | 90,018 |
| 2021-01-12 | Dorval Allison (Chief Financial Officer) | Sale | 2,942 | 8.62 | 25,360 |
| 2020-05-21 | Khwaja Omar (See remarks) | Sale | 3,500 | 12.96 | 45,360 |
| 2020-04-03 | Hesslein Robert W. (Senior VP & General Counsel) | Sale | 3,091 | 8.51 | 26,304 |
| 2020-01-21 | Turenne Andre (President & CEO) | Sale | 10,705 | 13.36 | 143,018 |
| 2020-01-21 | Ottmer Matthew P. (Chief Operating Officer) | Sale | 3,724 | 13.36 | 49,752 |
| 2020-01-21 | Dorval Allison (Chief Financial Officer) | Sale | 3,128 | 13.36 | 41,790 |
| 2019-03-12 | Neurocrine Biosciences Inc (10% Owner) | Buy | 4,179,728 | 11.96 | 50,002,086 |
| 2018-09-12 | Pierce Glenn (Director) | Buy | 5,000 | 18.44 | 92,200 |
| 2018-09-10 | Geraghty James A (Director) | Buy | 3,000 | 19.39 | 58,170 |
| 2018-08-17 | Geraghty James A (Director) | Buy | 3,000 | 18.31 | 54,929 |
| 2018-04-10 | Ravina Bernard (Chief Medical Officer) | Sale | 2,451 | 18.38 | 45,049 |
| 2018-03-23 | Henderson Jane (Sr. V.P. & CFO, Corp. Dev.) | Sale | 11,200 | 20.52 | 229,824 |
| 2018-03-23 | Henderson Jane (Sr. V.P. & CFO, Corp. Dev.) | Option Ex | 11,200 | 11.97 | 134,064 |
| 2018-03-22 | Henderson Jane (Sr. V.P. & CFO, Corp. Dev.) | Sale | 19,900 | 21.07 | 419,293 |
| 2018-03-22 | Henderson Jane (Sr. V.P. & CFO, Corp. Dev.) | Option Ex | 19,900 | 11.97 | 238,203 |
| 2018-03-19 | Henderson Jane (CFO & SVP, Corp. Dev.) | Sale | 1,900 | 21.76 | 41,344 |
| 2018-03-19 | Henderson Jane (CFO & SVP, Corp. Dev.) | Option Ex | 1,900 | 11.97 | 22,743 |
| 2018-03-16 | Henderson Jane (CFO & SVP, Corp. Dev.) | Sale | 15,416 | 22.15 | 341,464 |
| 2018-03-16 | Henderson Jane (CFO & SVP, Corp. Dev.) | Option Ex | 15,416 | 11.97 | 184,529 |
| 2018-03-12 | Ravina Bernard (Chief Medical Officer) | Sale | 2,451 | 25.16 | 61,667 |
| 2018-02-27 | Sah Dinah Ph.d. (Chief Scientific Officer) | Sale | 15,623 | 30.00 | 468,690 |
| 2018-02-27 | Sah Dinah Ph.d. (Chief Scientific Officer) | Option Ex | 15,623 | 9.63 | 150,449 |
| 2018-02-12 | Ravina Bernard (Chief Medical Officer) | Sale | 2,451 | 18.24 | 44,706 |
| 2018-01-10 | Ravina Bernard (Chief Medical Officer) | Sale | 3,630 | 16.40 | 59,531 |
| 2017-12-11 | Ravina Bernard (Chief Medical Officer) | Sale | 5,490 | 13.63 | 74,828 |
| 2017-11-10 | Ravina Bernard (Chief Medical Officer) | Sale | 5,490 | 13.26 | 72,797 |
| 2017-10-10 | Ravina Bernard (Chief Medical Officer) | Sale | 10,980 | 20.33 | 223,223 |
| 2017-09-11 | Ravina Bernard (Chief Medical Officer) | Sale | 10,980 | 14.30 | 157,014 |
| 2017-09-05 | Ravina Bernard (Chief Medical Officer) | Sale | 5,490 | 10.00 | 54,900 |
| 2017-07-20 | Ravina Bernard (Chief Medical Officer) | Sale | 5,490 | 10.00 | 54,900 |
| 2016-01-14 | Paul Steven M (President and CEO) | Buy | 10,000 | 14.07 | 140,690 |
| 2015-11-16 | Sanofi (Other) | Buy | 125,000 | 14.00 | 1,750,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of VYGR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Voyager Therapeutics, Inc. (symbol VYGR, CIK number 1640266) see the Securities and Exchange Commission (SEC) website.